Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres

• US 20030161889A1
• Filed: 08/20/2002
• Published: 08/28/2003
• Est. Priority Date: 03/16/1984
• Status: Abandoned Application

• Current Assignee: Charles Mcqueen, Edgar Boedeker, Frederick Cassels, Jean A. Setterstrom, John Vanhamont, Robert H. Reid
• Original Assignee: Charles Mcqueen, Edgar Boedeker, Frederick Cassels, Jean A. Setterstrom, John Vanhamont, Robert H. Reid
• Inventors: VanHamont, John, McQueen, Charles, Reid, Robert H., Setterstrom, Jean A., Boedeker, Edgar, Cassels, Frederick
• Application Number:
  US10/224,125
• Publication Number:
  US 20030161889A1
• Time in Patent Office: Days
• US Class Current: 424/491
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55505 Inorganic adjuvants
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0258 Escherichia
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/292 Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: C07K 14/245 Escherichia (G)
• CPC Class Codes: C12N 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention relates to an immunostimulating composition comprising encapsulating microspheres, which may contain a pharmaceutically-acceptable adjuvant, wherein said microspheres having a diameter between 1 nanometer (nm) to 10 microns (um) are comprised of (a) a biodegradable-biocompatible poly(DL-lactide-co-glycolide) as the bulk matrix, wherein the relative ratio between the amount of lactide and glycolide components are within the range of 40:60 to 0:100 and wherein said poly (DL-lactide-co-glycolide) is present in an uncapped form and an end-capped form wherin a ratio of uncapped to end-capped forms is 99/1 to 1/99, and (b) an immunogenic substance comprising Colony Factor Antigen (CFA/II), hepatitis B surface antigen (HbsAg), or a physiologically similar antigen that serves to elicit the producton of antibodies in animal subjects. The preparation of its composition and its use as a vaccine is also disclosed.

Claims

22. (New) An immunostimulating composition comprising encapsulating microspheres, wherein said microspheres comprise (a) a biodegradable-biocompatible poly (DL-lactide-co-glycolide) copolymer wherein said copolymer is present in an uncapped form and an end-capped form wherein a ratio of uncapped to end-capped forms is 99/1 to 1/99, and (b) an immunogenic substance which elicits production of antibodies at an intestinal mucosal surface in animal subjects to protect against infections caused by virus or bacteria.

23. (New) The immunostimulating composition of claim 22, wherein said immunogenic substance comprises Colony Factor Antigen (CFA/I), Colony Factor Antigen (CFA/II), AF/R1, hepatitis B surface antigen (HBSAg), or a physiologically similar antigen.

24. (New) A vaccine comprising the immunostimulating composition of claim 22.

25. (New) The immunostiumulating composition of claim 22, wherein said microspheres have a diameter of about 1 nanogram to about 12 microns.

26. (New) The immunositumulating composition of claim 22, wherein the relative ratio between an amount of lactide and glycolide components are within the range of 40:

60 to 0;

100.

27. (New) The immunositumulating composition of claim 22, wherein said immunogenic substance in present in an amount of 0.1 to 1.5% based on the volume of the bulk matrix.

28. (New) The immunositumulating composition of claim 22, wherein a relative ratio of lactide and glycolide components is 48:

52 to 58;

42.

29. (New) The immunositumulating composition of claim 27, wherein a size of more than 50% of said microspheres is between 5 and 10 um in diameter by volume.

30. (New) The immunostiumulating composition of claim 22, wherein said immunogenic substance is a synthetic peptide representing a peptide fragment beginning with the amino acid residue 63 through 78 of Pilus Protein CS3, said residue having the amino acid sequence, 63 (Ser-Lys-Asn-Gly-Thr-Val-Thr-Try-Ala-His-Glu-Thr-Asn-Asn-Ser-Ala) SEQ ID NO:

35.

31. (New) The immunostimulaing composition of claim 22, wherein said immunogenic substance elicits a production of antibodies that protect against intestinal infections caused by bacteria selected from the group consisting of Salmonella typhi, Shigella sonnei, Shigella flexneri, Shigella dysenteriae, Shigella boydii, Escheria coli, Vibro cholera, Yersinia, Staphylococcus, Chlostridium and Campylobacter..

32. (New) The immunositumulating composition of claim 22, wherein said microspheres are encapsulated within a gel capsule.

33. (New) The immunostimulating composition of claim 22, wherein said microspheres further comprise a pharmaceutically acceptable adjuvant.

34. The immunostimulating composition of claim 22, wherein said microspheres comprise smooth outer surfaces.

35. (New) The immunostimulating composition of claim 22, wherein about 63% of said microspheres are between 5 to 10 um.

37. (New) A vaccine comprising the immunostimulating composition of claim 22.

38. (New) The vaccine of claim 37, wherein said vaccine is in an oral form or an injectable form.

39. (New) The vaccine of claim 37, wherein said vaccine comprises a sterile, pharmaceutically-acceptable carrier.

40. (New) A method for vaccination against bacterial infection comprising administering to a human, an antibactericidally effective amount of the composition of claim 22.

41. (New) A method for vaccination against bacterial infection comprising administering to a human, an antivirally effective amount of the composition of claim 22.

42. (New) A diagnositc assay for bacterial infections comprising the composition of claim 22.

43. (New) A method of preparing an immunotherapeutic agent against infections caused by a bacteria comprising the step of immunizing a plasma donor with a vaccine according to claim 22 such that hyperimmune globulin is produced which contains antibodies directed against a bacteria.

44. (New) A method of preparing an immunotherapeutic agent against infections caused by a virus comprising the step of immunizing a plasma donor with a vaccine according to claim 22 such that hyperimmune globulin is produced which contains antibodies directed against a virus.

45. (New) The method of claim 44, wherein the virus is hepatitis B virus.

46. (New) An immunotherapy method comprising the step of administering to a subject an immunostimulatory amount of hyperimmune globulin prepared according to claim 43.

47. (New) An immunotherapy method comprising the step of administering to a subject an immunostimulatory amount of hyperimmune globulin prepared according to claim 44.

48. (New) A method for the protection against infection of a subject by enteropathogenic organisms or hepatitis B virus comprising administering to said subject an immunogenic amount of an immunostimulating composition of claim 22.

49. (New) A method according to claim 48, comprising administering said composition in four separate doses on day 0, day 7, day 14 and day 28.

50. (New) A method according to claim 48, wherein the immunogenic substance is the synthetic peptide representing the peptide fragment beginning with the amino acid residue 63 through 78 of Pilus Protein CS3, said residue having the amino acid sequence of 63(Ser-Lys-Asn-Gly-Thr-Val-Thr-Try-Ala-His-Glu-Thr-Asn-Asn-Ser-Ala) SEQ ID NO:

35.

51. (New) A method of producing AF/RI immune response in a subject comprising administering the composition of claim 22 to said subject in a dose of 15-150 ng/ml, wherein said immunogenic substance is AF/RI.

52. (New) A method of producing AF/RI immune response in a subject comprising administering the composition of claim 22 to said subject in a dose of 0.05 to 5.0 micrograms/ml, wherein said immunogenic substance is AF/RI.

53. (New) The composition of claim 22, wherein the molecular weight of the copolymer is 2,000 to 60,000 daltons.

36. (New) An immunostimulating composition comprising encapsulating microspheres, wherein said microspheres comprise (a) a biodegradable-biocompatible poly (DL-lactide-co-glycolide) as the bulk matrix, and (b) an immunogenic substance that serves to enhance spleen and Peyer'"'"'s patch B-cell responses to T &

B-cell epitopes.

54. (New) An immunostimulating composition comprising encapsulating microspheres, wherein said microspheres have a diameter between 1 nanometer and 10 microns, and wherein said microspheres comprise (a) a biodegradable-biocompatible poly (DL-lactide-co-glycolide) copolymer wherein said copolymer is present in an uncapped form and an end-capped form wherein a ratio of uncapped to end-capped forms is 99/1 to 1/99, wherein the relative ratio between the amount of lactide and glycolide components are within the range of 40:

60 to 0;

100 and (b) an immunogenic substance comprising Colony Factor Antigen (CFA/I), Colony Factor Antigen (CFA/TT), AF/R1, hepatitis B surface antigen (HBSAg), or a physiologically similar antigen which elicits the production of antibodies at an intestinal mucosal surface in animals.